Drugs / INCB047986
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01929941 | Sep 2013 → Aug 2014 | Hodgkins lymphoma, breast cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm +2 | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02093429 | Jan → Sep 2014 | myelodysplastic syndrome | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT02151474 | May → Aug 2014 | rheumatoid arthritis | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB047986 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01929941 ↗ |
| Known as | Incb-47986 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545225 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL3545225 ↗1“Novel JAK-inhibitor” NCT01929941 ↗ |
| Route | Oral | “INCB047986 tablets administered orally at the protocol specified dose and frequency” NCT01929941 ↗ |
| Target | JAK1 | “Tyrosine-protein kinase JAK1 inhibitor” CHEMBL3545225 ↗ |